BOLDENONE UNDECYLENATE (EQUIPOISE) (250 MG/ML – 10 ML)

Description

Boldenone Undecylenate

Strength: 250 mg/ml
Molecular Formula: C30H40O3
Molecular Weight: 452.66856 g/mol
Active Ingredient: Boldenone undecylenate
CAS number: 13103-34-9
Dosage Form: Injectable, oil base sterile solution
Route: Injection
Market Status: Prescription
Company: Hilma Biocare

DESCRIPTION

Boldenone Undecylenate 250 is an oily solution of boldenone undecylenate for IM injection.
Boldenone Undecylenate 250 is designed to release boldenone slowly from the injection
site. Boldenone serum levels will remain elevated for 5 to 8 days after administration.
Boldenone is an anabolic steroid possessing anabolic properties with moderate androgenic
activity. Anabolic and androgenic agents are widely used in the treatment of catabolic
processes where accelerated strength and muscular development are indicated.

CLINICAL PHARMACOLOGY

Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and
adverse reactions demonstrate the androgenic properties of these drugs. Complete
dissociation of anabolic and androgenic effects has not been achieved. The actions of
anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.
During exogenous administration of anabolic androgens, endogenous testosterone release
is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback inhibition of pituitary folliclestimulating hormone (FSH). Pharmacological studies involving laboratory animals have
demonstrated boldenone to have potent anabolic properties as well as moderate androgenic
activity. In clinical trials boldenone demonstrated a moderate to strong anabolic effect,
improved appetite, increased vigor, and improved musculature and strength.

INDICATIONS

Boldenone Undecylenate 250 is indicated as an alternate or adjunctive therapy in patients
for the promotion of weight gain following: weight loss and/or muscular atrophy associated
with extensive surgery, chronic infections, long term hospitali- zation, or severe trauma. For
increased RBC in severe anemic patients where first-line therapy is contraindicated. For
promotion of increased appetite in patients with appetite limited intake. Boldenone should be
considered only as an adjunctive therapy together with other androgenic medications.

ADVERSE REACTIONS

Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and
inorganic phosphates. Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver
function tests; rarely, hepatocellular neoplasms, peliosis hepatis, hepatic adenomas, and
cholestatic hepatitis. Hematologic: Suppression of clotting factors II, V, VII, & X: bleeding in
patients on anti- coagulant therapy. Nervous System: Increased or decreased libido,
headache, anxiety, depression, and generalized paresthesia. Other: Serum lipid changes,
hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.

CONTRAINDICATIONS

Patients with known hypersensitivity to any ingredients in this product. IA Patients with
known or suspected carcinomas of the breast, testis, or prostate. Patients with severe heart
disease, liver disease, or kidney disease or with a history of epilepsy. Products containing
androgens should not be used by women as they may cause and fetal harm. virilization

PRECAUTIONS

Because androgens may alter serum cholesterol concentration, caution should be used
when administering these drugs to patients with a history of myocardial infarction or coronary
artery disease. Patients on oral anticoagulant therapy require close monitoring especially
when androgens are started or stopped. Diabetics: androgens may alter the metabolism of
oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus
which may require adjustment of dosage of insulin and other hypoglycemic drugs.

PATIENT MONITORING

Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests –
AST/ALT. Prostatic specific antigen – PSA, Testosterone: total, free, and bioavailable.
Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate
should continue while androgen therapy, especially patients with difficulty in Urination or with
changes in voiding habits.

WARNING

Do conducted, In the absence of data on the effect of this drug on human subjects, 2 texsM
No human trials have been such use should be on a research basis only under the
supervision of a qualified physician.

DOSAGE AND ADMINISTRATION

Dosage has not been established. Use only pursuant to instructions of a qualified physician.

PRESENTATION

Boldenone Undecylenate ns 2i 250 mg/ml, 10 ml multiple dose vial.

STORAGE

Store in a cool dry place between 15 – 25°C, Protect from beau light.